

Supplementary Material

Antitubercular drug induced liver injury among tuberculosis patients in Central Ethiopia

Zelalem Petros^{1, 2*}, Anteneh Tamirat¹, Wondimu Assefa³

¹Department of Pharmacy, College of Medicine and Health Sciences, Wachemo University, Ethiopia.

²Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Addis Ababa University, Ethiopia.

³Department of Internal Medicine, Nigist Eleni Mohammed Memorial Comprehensive Specialized Hospital, Wachemo University, Ethiopia.

*Correspondence: Zelalem Petros, E-mail: zelalemp@yahoo.com

Anti-TB drug-induced liver injury in TB patients

Case Report Form (CRF)

I. Patient Identification

1. Date _____
2. Full Name _____ Code No. _____
3. Address: Sub city: _____ Woreda _____ House No _____
- Telephone No _____

II. Demography

4. Age: _____
5. Sex ☐ M ☐ F Height _____ Weight _____ BMI _____
6. Marital status: ☐ Single ☐ Married ☐ Divorced ☐ Widowed
7. Education: ☐ Illiterate ☐ Able to read & write ☐ Primary School
- ☐ Secondary School ☐ Tertiary
8. Occupation: ☐ Student ☐ Gov employed ☐ Self-employed ☐ Unemployed

III. Past medical history

Past medical problem	No	Yes	Not recall	Specify status	When
Pulmonary TB (PTB)				☐ AFB +ve ☐ AFB -ve ☐ GeneXpert	
Extra Pulmonary TB (EPTB)					
Known chronic liver disease					
History of recent alcohol intake				Beer or hard liquor or local drink (Tela, Tej, Katikala,...) in the past one month	
Any drug currently being taken				Specify	
Other past medical problems					

IV. Present Diagnosis

8. Type of TB ☐ Smear +ve PTB ☐ EPTB ☐ Disseminated TB
☐ Smear negative CXR suggestive PTB ☐ Others _____
9. Sign and symptoms of TB ☐ Fever ☐ Night sweating ☐ Cough
☐ Loss of appetite ☐ Weight loss
10. HIV status ☐ Positive ☐ Negative ☐ Unknown
11. CD4 count before ART initiation _____
12. HIV RNA before ART initiation _____

V. Drug treatment

13. When was the intensive phase of anti-TB started with “RHZE”? / /
dd mm yyyy
14. When was patient started on ART?
- ☐ After 1-week of anti-TB ☐ After 4-weeks of anti-TB ☐ After 8-weeks of anti-TB
15. ART initiated ☐ TDF/3TC/DTG ☐ TDF/3TC/EFV ☐ ZDV/3TC/EFV
16. List medications currently taken including the dose other than the ART.

Drug	Dose

Laboratory Follow up (TB+ve, HIV -ve)

Type of Lab	Normal range	Base line	4 th week	8 th week	12 th week	16 th week
Hgb	12.5-17 g/dL					
WBC	4.0-10.5 x 10 ³					
Neutrophils	1.8-7.8 x 10 ³					
Platelet	140-400 x 10 ³					
Urine HCG	Negative					
Sputum AFB	Negative					
AST	0-60 iu/L					
ALT	0-50 iu/L					
ALP	0-483 iu/L					
Bil (T)	0.1-1.1 mg/dL					
Albumin	3.5-5.5 g/dL					
HBsAg	Negative					
HCV Ab	Negative					

Laboratory Follow up (TB & HIV									
+ve) - ART at week									
Type of Lab	Normal range	Baseline	2 nd week	4 th week	8 th week	12 th week	16 th week	20 th week	
Hgb	12.5-17 g/dL								
WBC	4.0-10.5x 10 ³								
Neutrophils	1.8-7.8 x 10 ³								
Platelet	140-400x 10 ³								
Urine HCG	Negative								
Sputum AFB	Negative								
AST	0-60 iu/L								
ALT	0-50 iu/L								
ALP	0-483 iu/L								
Bil (T)	0.1-1.1mg/dL								
Albumin	3.5-5.5 g/dL								
HBsAg	Negative								
HCV Ab	Negative								
CD4	500-1400								
HIV RNA	Viral Load								

TB & HIV co infection – ART at the _____ week

Clinical signs and symptoms at scheduled visits

Signs and symptoms	Baseline	Scheduled visits (in weeks)				Remark
Nausea						
Anorexia						
Vomiting						
Fatigue						
Abdominal pain						
Fever						
Itching						
Icterus						
Skin rash						
Others (specify)						

Patient calendar for scheduled visits

[illegible]